Abstract：
:Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in this gene, which gives rise to decreased transcription of the gene product (called frataxin). Following these discoveries, drug discovery has moved at a rapid pace. Therapeutic trials in the next 5 years are expected to address amelioration of the effects of frataxin deficiency and methods for increasing frataxin expression. These therapies are directed at all levels of biochemical dysfunction in FA. Agents such as idebenone potentially improve mitochondrial function and decrease production of reactive oxygen species. Idebenone is presently in a phase III trial in the US and in Europe, with the primary outcome measure being neurological function. Deferiprone, an atypical iron chelator, may decrease build-up of toxic iron in the mitochondria in patients. It has entered a phase II trial in Europe, Australia and Canada directed toward improvement of neurological abilities. Finally, targeted histone deacetylase (HDAC) inhibitors and erythropoietin increase levels of frataxin when used in vitro, suggesting that they may provide methods for increasing frataxin levels in patients. Erythropoietin has been tested in a small phase II trial in Austria, while HDAC inhibitors are still at a preclinical stage. Symptomatic therapies are also in use for specific symptoms such as spasticity (baclofen). Thus, there is substantial optimism for development of new therapies for FA in the near future, and we suggest that one or several may be available over the next few years. However, continued development of new therapies will require creation of new, more sensitive measures for neurological dysfunction in FA, and clinically relevant measures of cardiac dysfunction.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Tsou AY,Friedman LS,Wilson RB,Lynch DRdoi
10.2165/00023210-200923030-00003subject
Has Abstractpub_date
2009-01-01 00:00:00pages
213-23issue
3eissn
1172-7047issn
1179-1934pii
3journal_volume
23pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract：:Tramadol-an atypical opioid analgesic-has a unique pharmacokinetic and pharmacodynamic profile, with opioidergic, noradrenergic, and serotonergic actions. Tramadol has long been used as a well-tolerated alternative to other drugs in moderate pain because of its opioidergic and monoaminergic activities. However, cumula...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-019-00623-5
更新日期：2019-05-01 00:00:00
abstract：:Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11587810-000000000-00000
更新日期：2011-05-01 00:00:00
abstract：:Several studies have found a correlation between the presence of circulating maternal autoantibodies and neuronal dysfunction in the neonate. Specifically, maternal anti-brain autoantibodies, which may access the fetal compartment during gestation, have been identified as one risk factor for developing autism spectrum...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0279-2
更新日期：2015-09-01 00:00:00
abstract：:gamma-Aminobutyric acid (GABA) is considered to be the major inhibitory neurotransmitter in the brain and loss of GABA inhibition has been clearly implicated in epileptogenesis. GABA interacts with 3 types of receptor: GABAA, GABAB and GABAC. The GABAA receptor has provided an excellent target for the development of d...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200115050-00001
更新日期：2001-01-01 00:00:00
abstract：:The development of an intervention to slow or halt disease progression remains the greatest unmet therapeutic need in Parkinson's disease. Given the number of failures of various novel interventions in disease-modifying clinical trials in combination with the ever-increasing costs and lengthy processes for drug develo...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0548-y
更新日期：2018-08-01 00:00:00
abstract：:Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200923060-00006
更新日期：2009-01-01 00:00:00
abstract：:There is escalating interest in cell-based therapies to restore lost dopamine inputs in Parkinson's disease. This is based upon the rationale that implanting dopamine progenitors into the striatum can potentially improve dopamine-responsive motor symptoms. A rich body of data describing clinical trials of previous cel...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-020-00727-3
更新日期：2020-06-01 00:00:00
abstract：BACKGROUND:Refractory status epilepticus (RSE) is an emergency with high mortality requiring neurointensive care. Treatment paradigms include first-generation antiepileptic drugs (AEDs) and anesthetics. Lacosamide (LCM) is a new AED, holding promise as a potent treatment option for RSE. High-level evidence regarding sa...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-013-0049-y
更新日期：2013-04-01 00:00:00
abstract：:For nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressa...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418080-00003
更新日期：2004-01-01 00:00:00
abstract：:All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-014-0177-z
更新日期：2014-07-01 00:00:00
abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0075-9
更新日期：2013-06-01 00:00:00
abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-013-0102-x
更新日期：2013-11-01 00:00:00
abstract：:Restless legs syndrome (RLS) is a common, frequently chronic, sensorimotor neurological disorder characterized by nocturnal leg dysesthesias and an irresistible urge to move the legs, usually resulting in sleep disturbance. Dopaminergic agonists, alpha-2-delta calcium-channel ligands, and opioids have all demonstrated...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0250-2
更新日期：2015-05-01 00:00:00
abstract：OBJECTIVE:Many authors have reported discontinuation symptoms associated with selective serotonin reuptake inhibitors (SSRIs). The aim of this study was to investigate the incidence and characteristics of the discontinuation syndrome in patients who stopped treatment with the SSRIs paroxetine and fluoxetine under the u...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.2165/00023210-200216040-00006
更新日期：2002-01-01 00:00:00
abstract：OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...
journal_title：CNS drugs
pub_type： 临床试验,杂志文章
doi：10.2165/00023210-200620110-00006
更新日期：2006-01-01 00:00:00
abstract：:Once considered rare and resistant to treatment, obsessive-compulsive disorder (OCD) has now emerged as a common, yet often unrecognized, psychiatric condition. Treatment with selective serotonin reuptake inhibitors (SSRIs) is effective in 40-60% of patients with OCD. Management of the remaining 40-60% of patients wit...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11587860-000000000-00000
更新日期：2011-07-01 00:00:00
abstract：OBJECTIVE:To determine the efficacy and tolerability of zolmitriptan 2.5 mg oral tablet as an acute treatment for menstrual migraine attacks. METHODS:This was a two-phase, multicentre, randomised, double-blind, placebo-controlled, parallel-group outpatient study (Phase I is reported here). The study was conducted at 2...
journal_title：CNS drugs
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.2165/00023210-200620120-00005
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...
journal_title：CNS drugs
pub_type： 杂志文章,meta分析,评审
doi：10.2165/11634500-000000000-00000
更新日期：2012-09-01 00:00:00
abstract：:As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication through...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200620100-00001
更新日期：2006-01-01 00:00:00
abstract：:Cytomegalovirus (CMV) infection of the CNS occurs most commonly in patients with severe immunosuppression such as those with advanced HIV infection (i.e. AIDS) or those who have undergone bone marrow or solid organ transplantation. Immunocompetent patients are affected very rarely. The infection of the CNS may affect ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216050-00003
更新日期：2002-01-01 00:00:00
abstract：:The aim of this review is to provide clinicians with a picture of the mechanisms by which: histamine and histaminergic agonists act on the vestibular system both peripherally and centrally; and histaminergic agonists and antagonists interfere with the recovery process after peripheral vestibular lesion. We have focuse...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200115110-00004
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Statin use has been frequently associated with depressive symptoms in an older population. However, the nature of this association is uncertain in the literature. In this study, we aimed to investigate the association of statin intake and the prevalence of depressive symptoms in healthy community-dwelling ol...
journal_title：CNS drugs
pub_type： 杂志文章,随机对照试验
doi：10.1007/s40263-019-00633-3
更新日期：2019-07-01 00:00:00
abstract：:Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...
journal_title：CNS drugs
pub_type： 评论,杂志文章
doi：10.2165/00023210-200822030-00006
更新日期：2008-01-01 00:00:00
abstract：INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-016-0359-y
更新日期：2016-07-01 00:00:00
abstract：:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418150-00004
更新日期：2004-01-01 00:00:00
abstract：:Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0041-6
更新日期：2013-03-01 00:00:00
abstract：:Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult(®); Tyvense Adult™) has been approve...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-016-0327-6
更新日期：2016-04-01 00:00:00
abstract：:Schizophrenia is a long-term psychiatric disorder that impacts important mental functions and requires indefinite treatment, as well as psychosocial and economic support. The introduction of chlorpromazine, the first antipsychotic, and the subsequent development of a long list of similar dopamine-blocking antipsychoti...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0588-3
更新日期：2019-01-01 00:00:00
abstract：:A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/0023210-200822120-00005
更新日期：2008-01-01 00:00:00
abstract：:There have been significant developments in the understanding of depression in children and adolescents in the past few years, including an increased recognition that significant depressive illness occurs in this patient group. Pharmacological and psychotherapeutic treatments are used to manage depression in children ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200620010-00001
更新日期：2006-01-01 00:00:00
